ALMAC DISCOVERY LTD has a total of 175 patent applications. It decreased the IP activity by 14.0%. Its first patent ever was published in 2007. It filed its patents most often in United Kingdom, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are CSTONE PHARMACEUTICAL SUZHOU CO LTD, ALLGENESIS BIOTHERAPEUTICS INC and BEIJING XINTIANYU TECHNOLOGY DEV CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United Kingdom | 32 | |
#2 | WIPO (World Intellectual Property Organization) | 22 | |
#3 | EPO (European Patent Office) | 15 | |
#4 | Australia | 12 | |
#5 | Canada | 12 | |
#6 | China | 12 | |
#7 | Israel | 10 | |
#8 | Republic of Korea | 10 | |
#9 | Singapore | 10 | |
#10 | United States | 10 | |
#11 | Brazil | 8 | |
#12 | Mexico | 7 | |
#13 | New Zealand | 4 | |
#14 | South Africa | 4 | |
#15 | Hong Kong | 3 | |
#16 | Hungary | 2 | |
#17 | Chile | 1 | |
#18 | Serbia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology | |
#4 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Heterocyclic compounds | |
#3 | Medical preparations | |
#4 | Peptides | |
#5 | Microorganisms | |
#6 | Enzymes |
# | Name | Total Patents |
---|---|---|
#1 | Burkamp Frank | 88 |
#2 | Harrison Timothy | 68 |
#3 | O'Dowd Colin | 44 |
#4 | Rountree James Samuel Shane | 39 |
#5 | Wilkinson Andrew John | 31 |
#6 | Miel Hugues | 27 |
#7 | Hewitt Peter | 26 |
#8 | O'Dowd Colin Roderick | 25 |
#9 | Zhang Lixin | 24 |
#10 | Trevitt Graham | 23 |
Publication | Filing date | Title |
---|---|---|
GB202020154D0 | ROR1-specific variant antigen binding molecules | |
GB202001980D0 | Therapeutic mentods | |
WO2020115500A1 | Usp19 inhibitors for use in therapy | |
WO2020115501A1 | Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19) | |
GB201914267D0 | Pharmaceutical compounds | |
GB201911311D0 | Pharmaceutical compounds | |
GB201908886D0 | Anthracycline derivatives | |
GB201904341D0 | Therapeutic methods | |
GB201904339D0 | Pharmaceutical compounds | |
GB201819937D0 | Pharmaceutical compounds | |
GB201819936D0 | Therapeutic methods | |
GB201800378D0 | Pharmaceutical compounds | |
GB201721802D0 | Ror1-specific antigen binding molecules | |
MX2019004450A | Piperidine derivatives as inhibitors of ubiquitin specific protease 7. | |
AU2017282084A1 | Treatment of ocular disease | |
GB201705435D0 | Treatment of ocular disease | |
GB201703881D0 | Pharmaceutical compounds | |
GB201612938D0 | Pharmaceutical compounds | |
GB201612095D0 | Pharmaceutical compounds | |
GB201612092D0 | Pharmaceutical compounds |